Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03597438 · ClinicalTrials.gov registry record
National CounterACT Initiative
A clinical trial, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- 236
- Enrollment target
NCT03597438: Completed study, sponsored by Children's Hospital of Philadelphia.
NCT03597438 is a clinical trial that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 236 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03597438 has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- 236 participants
- Enrollment target
Study Summary
The purpose of the study is to determine in vitro effects on mitochondrial function of selected chemical agents in human cells, and assess the capability of a cell-permeable succinate prodrug to attenuate toxic effects The project aims at repurposing this recent pharmaceutical discovery, currently being developed for treatment of toxic exposure, for an expanded indication to treat chemically induced mitochondrial toxicity.
Primary Outcome
Data will be assessed using 2-tailed Student's t-test. Dose-response curves for respiration will be made for each toxin and IC50 calculated. In case of difficulties in demonstrating acute toxicity of chemical agents, dose-titration experiments and long-term incubation (up to 24 hours) will be performed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2018-05-07 |
| Est. Completion | 2024-02-22 |
What the finished NCT03597438 record still lists
NCT03597438 is an observational study that tracks outcomes without assigning an intervention. The registered 236 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03597438 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03597438 about?
NCT03597438 is a clinical study titled "National CounterACT Initiative". The purpose of the study is to determine in vitro effects on mitochondrial function of selected chemical agents in human cells, and assess the capability of a cell-permeable succinate prodrug to attenuate toxic effects The project aims at repurposing this recent pharmaceutical discovery, currently b...
What is the current status of trial NCT03597438?
This trial is currently completed. The enrollment target is 236 participants. The study started on 2018-05-07. Estimated completion is 2024-02-22.
Who is sponsoring clinical trial NCT03597438?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04995341 · 236 participants · NA
Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)
- NCT05822362 · 236 participants · Phase 2
CBD for Individuals at Risk for Alzheimer's Disease
- NCT06200103 · 236 participants · Phase 2
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
- NCT06494072 · 236 participants · Phase 4
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI